COCH Stock — Envoy Medical Inc.

Envoy Medical Inc. (COCH)

Updated October 16, 2026.

COCH is a Stock. Total return is -93.2% over the past 5.5 years, 188.7 points behind SPY at 95.5%.

Envoy Medical is a hearing health company that develops and provides medical technologies across the hearing loss spectrum, including personal sound amplification devices, hearing aids, fully implanted active middle ear implants, auditory osseointegrated implants, and cochlear implants. The company does not currently have an established distribution schedule. This security may appeal to investors seeking exposure to the medical device sector without reliance on regular dividend income.

COCH performance versus SPY

Price and return data through 2026-10-16.

Total return is -93.2% over the past 5.5 years, 188.7 points behind SPY at 95.5%. Over the past year its total return — price change plus distributions reinvested — is -21.4%. Its deepest 1-year drawdown was 54.6%.

COCH key facts

Asset type

Stock

Asset class

Equity

Inception date

04/29/2021

Distribution frequency

None

Last close

$0.67 (as of 2026-10-16)

Market cap

$51,565,989

Average volume

41341.0

Beta

1.948

Payout ratio

0.0%

EPS

$-0.76

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

COCH risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 54.6%.

Who may consider COCH — and who may not

It is a weaker fit for investors who need monthly cash flow (COCH does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on COCH

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions